Primary and Secondary Prevention Flashcards

1
Q

Primary prevention
- Definition
- Examples

A
  • preventing the health problem; the most cost-effective form of healthcare
  • immunizations, counseling about safety, and disease prevention (diet & exercise, gun safety, counseling)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Secondary prevention
- Definition
- Examples

A
  • detecting disease in early, asymptomatic, or preclinical state to minimize its impact
  • Screening/survey tests (BP check, mammography, colonoscopy, labs, PSA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Tertiary prevention
- Definition
- Examples
- Test Tip:

A
  • minimizing negative disease-induced outcomes
  • In established disease, adjusting therapy to avoid further target organ damage; potentially viewed as a failure of primary prevention
  • Intervene at lowest level of prevention possible
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is avoided annually by vaccination in USA?

A
  • Polio –> 10,000 children are not paralyzed; 3,000 children deaths are avoided
  • Rubella (German measles) –> 20,000 newborns spared congenital rubella syndrome
  • Measles –> Saves 12,000 deaths in US and 2.7 mil worldwide (most children)
  • Influenza –> Avoids ~7 mil cases of flu illness, 110,000 hospitalizations, and ~9,000 deaths (children, elderly, and pregnant women)
  • Pneumococcal disease –> ~40,000 deaths annually (50% could be prevented); 1/20 die from pneumonia, 1/5 die from septicemia and meningitis)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The results of vaccinations in the USA:

A
  • EBP advises that vaccine-related risk < disease-related risk
  • Cost of vaccines outweighed against expense of treating vaccine-preventable diseases (VPD)
  • Higher immunization rates contribute to herd/community immunity where even the unimmunized have a degree of protection d/t less opportunity to spread
  • Advocating patients protection against VPD is one of the most important primary prevention activities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Immunization (IZ) principles

A
  • Remove geographic and clinical practice barriers whenever possible (reach out to populations in need including senior centers, schools, worksites, retail centers, etc)
  • When in doubt, re-immunize (Better to give an extra vaccine dose than to give none; risk of reaction to reimmunization is minimal)
  • IZ deferred = IZ denied (Presence of minor illness does not necessitate deferring or delaying immunization; Immunization should be deferred only in the presence of moderate-to-severe illness with or without fever)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Active Immunity
- Definition
- Why active immunity?
- Onset of protection?
- Duration of protection?

A

Active immunity via immunization

Resistance developed in response to a vaccine and usually characterized by the presence of an antibody produced by host

Protection on board in anticipation of possible exposure

Onset of protection: Usually within 1 month of vaccine dose

Duration of protection: Usually years or lifelong

Available for the prevention of a wide variety of infectious diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Passive Immunity
- Definition
- Why passive immunity?
- Onset of protection?
- Duration of protection?

A

Passive immunity via administration of immune globulin)

Immunity conferred by an antibody produced in another hot by administration of an antibody-containing preparation (antiserum or immune globulin [IG])

Given post-exposure to select infecting agents, patient needs to present with risk or report of exposure

Onset of protection: Usually within hours of dose

Duration of protection: Usually time-limited, usually 6-9 months

Available for a limited number of infectious diseases including varicella, hepatitis A/B, tetanus, rabies, etc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Tetanus Prophylaxis in Wound Management
Clean, minor wounds
(Tdap/Td IM or TIG?)
1. Hx of tetanus vaccinations
2. Unknown or <3 doses
3. >/= 3 doses

A
  1. Tdap or Td IM
  2. Yes
  3. No, unless >10 years since last dose
  4. TIG, 250 units IM
  5. No
  6. No

TIG = Tetanus Immunoglobulin
Td = Tetanus diphtheria
Tdap = Tetanus, diphtheria, acellular pertussis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tetanus Prophylaxis in Wound Management
All other wounds
(Tdap/Td IM or TIG?)
1. Hx of tetanus vaccinations
2. Unknown or <3 doses
3. >/= 3 doses
4. What are considered other wounds?

A
  1. Tdap or Td IM
  2. Yes
  3. No, unless >5 years since last dose
  4. TIG, 250 units IM
  5. Yes
  6. No
  7. Wounds >6 hours old; contaminated with soil, saliva, feces, or dirt; puncture or crush wounds; avulsions; wounds from missiles, burns, or frostbite
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tetanus Prophylaxis in Wound Management Considerations
1. Which vaccination should be considered for <7 year olds? What if pertussis is contraindicated?
2. A single booster of which vaccine is recommended for adolescents and adults?
3. A dose of which vaccine is indicated during pregnancy regardless of vaccination history?
4. Test Tip regarding true vaccination contraindications:

A
  1. DTaP should be used for children age <7 years old (DT if pertussis vaccine is contraindicated)
  2. A single booster dose of Tdap is recommended for adolescents and adults to replace one Td booster
  3. A dose of Tdap is recommended during each pregnancy regardless of prior history of taking Tdap
  4. True vaccine contraindications are rare. Localized vaccine reactions are common and self-limiting.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Personalized IZ Contraindications
If patient has a history of anaphylactic (not localized), reaction to the following, avoid which IZ?
1. Neomycin
2. Streptomycin, polymyxin B, neomycin
3. Baker’s yeast
4. Gelatin, neomycin
5. Gelatin
6. Eggs

A
  1. IPV, MMR, varicella
  2. IPV, vaccinia (smallpox)
  3. Hepatitis B
  4. Varicella zoster (Zostavax)
  5. MMR
  6. Nothing. Eggs have been removed.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Anaphylaxis (regarding IZ)
1. Definition
2. Causes
3. Most common presentation
4. Provider Precaution and Preparation for anaphylaxis risk

A
  1. An acute, life-threatening systemic reaction with varied mechanisms, clinical presentations, and severity that results from the sudden systemic release of mediators from mast cells and basophils
  2. From any cause, including drug reaction, bee sting, immunization, food allergy, etc
  3. Urticaria (hives), angioedema (tissue edema most often involving the head and neck), and respiratory compromise
  4. Risk is low (1-2 events per 1 mil vaccine doses given), all vaccines should be administered in settings in which personnel and equipment for rapid recognition and treatment of anaphylaxis are available
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Anaphylaxis
1. Definition
2. Presentation

A
  1. Acute onset of an illness (minutes to several hours) after exposure to allergen with involvement of:
  2. Skin and/or mucosa (pruritis/itch, urticaria/hives, and angioedema)
    AND EITHER
    Respiratory compromise (Dyspnea, wheeze/bronchospasm, stridor)
    OR
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Anaphylaxis
1. Definition
2. Presentation

A
  1. Acute onset of an illness (minutes to several hours) after exposure to allergen with involvement of:
  2. Skin and/or mucosa (pruritis/itch, urticaria/hives, and angioedema) (1 of these)
    AND EITHER
    Respiratory compromise (dyspnea, wheeze/bronchospasm, stridor) (1 of these OR 1 of the below)
    OR
    ↓ BP or end-organ dysfunction (collapse, syncope, incontinence)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Immediate interventions in anaphylaxis in primary care

A
  1. Assess ABC (airway, breathing, circulation)
  2. Place patient in supine position
  3. Activate EMS, facilitate transfer to ED
  4. Administer IM epinephrine (anterior-lateral thigh)
    Note: NO contraindications to epinephrine use in anaphylaxis regardless of comorbidity or age
  5. Give H1/H2 blocker PO (H1=Diphenhydramine, H2= Ranitidine) - Ideally liquid
  6. IV access, oxygen, ongoing clinical monitoring - Repeat epi Q5min dictated by response
  • Generally, Epi is contraindicated in pregnancy, MI, stroke but NOT in anaphylaxis!
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Anaphylaxis
In the ED, interventions based on initial response:

  • Referral?
  • What is biphasic reaction?
A
  1. Establish airway if compromised
  2. Rapid fluid infusion (IV, IO) as needed for compromised circulation
  3. Repeat IM epinephrine as needed or consider IV epinephrine infusion
  4. Bronchodilators based on respiratory compromise
  5. Systemic corticosteroids
  6. Glucagon
  7. Length of observation based on clinical presentation, response to therapy, risk factors for fatal anaphylaxis, access to medical care, reliability – Need referral to allergist

Biphasic Reaction –> Reaction again in 4 hours after initial better

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Anaphylaxis
Determine disposition: Home vs Admission considerations

A

Based on presentation and response to therapy in ED
* Home (most common) – With patient education on the use of self-injected epinephrine (EpiPen, SIE), potential biphasic reaction, trigger avoidance. Consider prescriptions for oral antihistamines and systemic corticosteroids

  • Admission – Inpatient or ICU depends on persistent respiratory and/or circulatory compromise
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

In a community undergoing a disaster, the use of select vaccines will be prioritized. Which vaccine or immunization is prioritized in the following types of disasters?
1. Uninjured adults and children evacuated to a crowded group setting
2. Adults with multiple deep lacerations from flying debris
3. A community exposed to unsafe water supply after a hurricane

A
  1. Immunization against influenza
  2. Immunization against tetanus
  3. Immunizations against hepatitis A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

True or false:
1. Immune globulin is a concentrated solution of antibodies derived from pooled donated blood
2. Previously unvaccinated adults with diabetes mellitus type 1 or type 2 should be vaccinated against hepatitis B as soon as possible after the diabetes diagnosis is made
3. Given that contraindications to influenza vaccine are rare, nearly everyone >/= 6 months of age should be encouraged to receive this immunization

A
  1. True. Jehovah’s witness may refuse
  2. True. Risk for developing chronic HBV (ages 19-59), contracting HBV through group glucose testing; ages 19-59 are 2-9x more likely to get Hep B
  3. True.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Live, Attenuated Virus Vaccines
1. Definition
2. Examples + Precautions for use in special populations

A
  1. Vaccine prepared from live microorganisms cultured under adverse conditions leading to loss of virulence but retention of their ability to induce protective immunity
  2. MMR (measles, mumps, rubella)
    Varicella (chickenpox)
    Intranasal influenza virus vaccine (FluMist)
    * Pregnancy, d/t theoretical risk of passing virus to unborn child –> can cause infection
    * In severe immunocompromised, d/t potential risk of becoming ill with virus or lack of clinical effect (live vaccines does not work well)
    * See pediatric and adult immunization guidelines for further info on using live virus vaccines with HIV infection ( CD4 <200; if benefit outweigh risks, give vaccine)

Rotavirus vaccine (oral vaccine only given to young infants)
* Use contraindicated in infants diagnosed with severe combined immunodeficiency (SCID), a condition readily recognized in early infancy or history of intussusception (lower GI obstruction)
* Harmless virus shed from stool in first weeks post-vaccine
* Standard diaper hygiene and handwashing advisable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Indicate if each of the following individuals should receive vaccination with zoster vaccine recombinant (Shingrinx), yes or no?
1. A 50-year-old woman who will start treatment with adalimumab (Humira) for rheumatoid arthritis therapy in 2 weeks
2. A 65-year-old man who received one dose of zoster vaccine live (Zostavax) 5 years ago
3. A 55-year-old man who had shingles 3 months ago and all signs and symptoms have resolved

A
  1. Yes.
  2. Yes. At least 8 weeks from the zostavax
  3. Yes. Give vaccine as long as lesions are crusted over
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Comparison of Herpes Zoster (Shingles) vaccines:
Shingrix vs Zostavax
1. Vaccine type
2. Dosing
3. FDA indication
4. Contraindications
5. ACIP recommendation
6. Most common adverse events
7. Do not give in which population?
8. Billing?

A

Shingrix
– zoster vaccine recombinant, adjuvanted, no live virus, near 100% efficacy, few exclusions to use, preferred zoster vaccine
1. Recombinant, adjuvanted (last up to 9 years)
2. 2 doses at 0 and 2-6 months, IM
3. Prevention of herpes zoster (shingles) in adults aged 50 years or older
4. Hx of severe allergic reactions to any component of vaccine. Able to be given in immune suppression; not studied or advised for use in pregnancy
5. Adults age >/=50 years, including those who previously received live zoster vaccine
6. Local – pain at injection site (78%), redness at injection site (38.1%), swelling (25.9%)

General – Myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), GI symptoms (17.3%)

Zostavax
– zoster vaccine line, ~50% efficacy, many exclusions to use, no longer used
1. Live, attenuated virus (lasts up to 6-7 years)
2. One dose, subQ
3. Prevention of herpes zoster (shingles) in individuals 50 years of age or older
4. Hx os severe allergic reaction to any component of vaccine; immunosuppression, immunodeficiency, pregnancy
5. Immunocompetent adults aged >/= 60 years
6. Injection site reaction (63.6%), headache (9.4%)

  1. Do not give in pregnancy
  2. Medicare under part D (drug pharmacy) - Bill for vaccination (Trasx-Rx)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Know ACIP Recommendations on Influenza Immunization

A
  • Egg allergies removed as a contraindication to getting the flu shot
  • Flu: most optimized time to obtain is Sept-Oct
  • For ages 6 months and older, annually
  • Pregnant women should get vaccinated
  • When limited supply, vaccinations should be given to persons at higher risk for complications
  • Avoid if anaphylactic reaction
  • Consider observing patients for 15 minutes after vaccination to decrease risk of injury if syncope
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Common reactions to immunization

A
  • discomfort and erythema at injection site, generally expected
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Hepatitis B

A

1st dose: Birth
2nd dose: 1-2 months
3rd: 6-18 months

*4 weeks between doses 1 and 2
*8 weeks between doses 2 and 3 + 16 weeks after 1st dose

For children 7-18 years
*b/w dose 1 and 2: 4 weeks
*b/w dose 2 and 3: 8 weeks and at least 16 weeks after 1st dose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Rotavirus
- RV1 (2-dose series)
- RV2 (3-dose series)

A

1st dose: 2 months
2nd dose: 4 months

*4 weeks between dose 1 and 2
*Minimum age for 1st dose is 6 weeks, maximum age for 1st dose is 14 weeks, 6 days
* Maximum age for final dose is 8 months, 0 days

  • Contraindicated SCID (severe combined immunodeficiency)
  • Precaution in HIV infection; give if benefit outweighs risk
  • N/A in pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Diphtheria, tetanus, acellular pertussis (DTaP <7 years)

A

1st dose: 2 months
2nd dose: 4 months
3rd dose: 6 months
4th dose: 15-18 months
5th dose: 4-6 years

*Minimum age for 1st dose is 6 weeks
*4 weeks between dose 1 and 2
*4 weeks between dose 2 and 3
*6 months between dose 3 and 4
*6 months between dose 4 and 5

  • N/A in pregnancy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Haemophilus influenzae type b (Hib)

A

1st dose: 2 months
2nd dose: 4 months
3rd dose: 6 months
3rd or 4th dose: between 12 and 18 months

*Minimum age for 1st dose: 6 weeks
*4 weeks between dose 1 and 2 if 1st dose before 12 months (1st birthday)
* 8 weeks (as final dose) if first dose was given between 12 and 14 months
-No further doses needed if first dose was given at 15 months or older

In general, do not give Hib after 5 months – Hib does not affect >59 months (6 years old)

*8 weeks (as final dose) between dose 3 and 4 ONLY necessary for children 12 - 59 months who received 4 doses before their 1st birthday

  • N/A in pregnancy
  • Recommended w/ additional dose if medical condition warrants in immunocompromised and HIV patients, Asplenia/persistent complement component deficiencies
30
Q

Pneumococcal conjugate (PCV13)

A

B1st dose: 2 months
2nd dose: 4 months
3rd dose: 6 months
4th dose: 12-18 months

*Minimum age for 1st dose: 6 weeks
*4 weeks if 1st dose was given before 1st birthday
*8 weeks (as final dose for health children) if 1st dose was given at 1st birthday or after
- No further doses needed for health children if 1st dose was given 24 months or older

Between doses 1 and 2:
*4 weeks if current age is <12 and previous dose was given at <7 months
* 8 weeks (final dose for healthy children) if previous dose was given between 7-11 months, wait until 12 months OR if current age is >/=12 months and at least 1 dose was given before 12 months
- No further doses for healthy children if previous dose was given at age 24 months or older

Dose 3 to 4:
*8 weeks (as final dose); only necessary for children 12-59 months and received 3 doses before 12 months or for children at high risk who received 3 doses at any age

  • N/A in pregnancy
  • Recommended w/ additional dose if medical condition warrants in immunocompromised and HIV patients, kidney failure/ESRD, heart/CV disease; CSF leak or cochlear implant, Aspelnia or persistent complement component deficiencies, chronic liver disease, diabetes
31
Q

Inactivated poliovirus (IPV <18 years)

A

1st dose: 2 months
2nd dose: 4 months
3rd dose: 6-18 months
4th dose: 4-6 years

*Minimum age for 1st dose: 6 weeks
*b/w dose 1 and 2: 4 weeks
*b/w dose 2 and 3: 4 weeks if current age is <4 years; 6 months (final dose) if current age is >/= 4+years
*b/w dose 3 and 4: 6 months (min age 4 years for final dose)

  • Caution in pregnancy, give if benefit outweighs risk
32
Q

Influenza (IIV) or Influenza (LAIV4)

A

IIV: Annual vaccination 1-2 doses between 6 months to 4-6 years; then annual 1 dose

LAIV4: Annual vaccine 1-2 doses between 2-3 years and 4-6 years; then annual 1 dose
- Caution in kidney failure/ESRD, heart/CV disease, chronic liver disease, diabetes; give if benefit outweigh risk
- Contraindicated in pregnancy, immunocompromised, HIV+, Asthma/wheezing 2-4 years, CSF leak/cochlear implant, asplenia/persistent complement component deficiencies

33
Q

Measles, mumps, rubella (MMR)

A

1st dose: 12-15 months
2nd dose: 4-6 years

*Minimum age for 1st dose: 12 months
*b/w dose 1 and 2: 4 weeks

-Contraindicated in pregnancy, immunocompromised, HIV+ (vaccinate after pregnancy)

34
Q

Varicella (VAR)

A

1st dose: 12-15 months
2nd dose: 4-6 years

*Minimum age for 1st dose: 12 months
*b/w dose 1 and 2: 3 months

-Contraindicated in pregnancy, immunocompromised, HIV+ (vaccinate after pregnancy)

35
Q

Hepatitis A (Hep A)

A

2-dose series between 12 - 19-23 mos

*min age for 1st dose: 12 months
*b/w dose 1 and 2: 6 months

For children 7-18:
*b/w dose 1 and 2: 6 months

36
Q

Tetanus, diphtheria, acellular pertussis (Tdap >/= 7 years)

A

13-15 years

*min age for 1st dose: 7 years
*b/w dose 1 and 2: 4 weeks
*b/w dose 2 and 3: 4 weeks if 1st dose was given before 1st birthday; 6 months (final dose) if 1st dose was given at or after 1st birthday
*b/w dose 3 and 4: 6 months, if 1st dose was given before 1st birthday

1 dose Tdap, then Td or Tdap booster every 10 years

  • Recommended in pregnancy, with additional doses depending on medical condition; 1 dose for each pregnancy
  • 1 dose for wound management; for clean/minor. give 1 dose if last dose >10 years; for all other wounds, give 1 dose if last dose >5 years
37
Q

Human papillomavirus (HPV)

A

1st dose: 11-12 years

*min age for 1st dose: 9 years

  • Routine dosing intervals are recommended
  • Contraindicated in pregnancy, vaccine after pregnancy
  • Recommended with additional doses depending on medical conditions: immunocompromise, HIV+

Age 19-36: 2-3 doses depending on age at initial vaccination or condition

38
Q

Meningococcal

A

*Min age for 1st dose:
MenACWY-DRM >/= 2 months
MenACWY-D >/= 9 months
MenACWY-TT >/= 2 years
*b/w dose 1 and 2: 8 weeks

For children 7-18 years:
1st dose: 11-12 years
2nd dose: 16 years

*min age for 1st dose: N/A
*b/w dose 1 and 2: 8 weeks

39
Q

Inactivated Poliovirus (ages 7-18)

A

B/w dose 1 and 2: 4 weeks

B/w dose 2 and 3: 6 months; a 4th dose is not necessary if 3rd dose was given at age 4 or older and at least 6 months after previous dose

4th dose: indicated if all previous doses were given <4 years or if the 3rd dose was given <6 months after the 2nd one

40
Q

MMR (7-18 years) + Adult

A

B/w dose 1 and 2: 4 weeks

19 - >65 years: 1 or 2 doses depending on indication (if born in 1957 or later); recommended if meet age requirement, lack documentation of vaccination, or lack evidence of past infection

41
Q

Varicella (7-18 years) + Adult

A

B/w dose 1 and 2: 3 months if <13 years; 4 weeks if >/= 13 years

Age 19 - 50: 2 doses (if born in 1980 or later)
Ages 50 - >65: 2 doses

4-8 weeks apart if previously did not receive varicella-containing vaccine

42
Q

Zoster recombinant (RZV)

A

Shingrix
Started at age 50: 2 doses
2-6 months apart
- min interval: 4 weeks, repeat dose if given too soon regardless of previous herpes zoster or hx of zoster vaccine live

43
Q

Pneumococcal conjugate (PCV13)

A

Age 19 - >65: 1 dose
Recommended for adults with an additional risk factor or another indication

> 65: vaccine based on shared clinical decision-making

  • N/A for pregnancy
  • Recommended for immunocompromise, HIV+, asplenia/complement deficiencies, ESRD/on HD
  • Consider in heart/CV disease, chronic liver disease, diabetes, health care personnel, gay men
44
Q

Pneumococcal polysaccharide (PPSV23)

A

19 - >65: 1-2 doses depending on indication
>65: Recommended 1 dose for meet age requirement, lack documentation of vaccination or lack evidence of past infection

  • For pregnancy if have additional risk factors or another indication; consider same for health care personnel, gay men
  • Recommended if lack of vaccine or lack of past infection: immunocompromise, HIV+, asplenia/complement deficiencies, ESRD/on HD, heart/CV disease, chronic liver disease, diabetes
45
Q

Hepatitis A (Adults)

A

19 - >65: Recommended 2-3 doses depending on additional risk factors or other indication

  • For pregnancy and immunocompromise if have additional risk factors or another indication; consider same for asplenia/complement deficiencies, ESRD/on HD, heart/CV disease, diabetes, health care personnel, gay men
  • Recommended if lack of vaccine or lack of past infection: HIV+, chronic liver disease
46
Q

Hepatitis B (Adults)

A

19 - >65: Recommended 2-3 doses depending on additional risk factors or other indication (2, 3, or 4 doses depending on vaccine or condition)

  • For pregnancy and immunocompromise if have additional risk factors or another indication; consider same for asplenia/complement deficiencies, heart/CV disease
  • Recommended if lack of vaccine or lack of past infection: HIV+, ESRD/on HD, chronic liver disease, diabetes, health care personnel, gay men
47
Q

Meningococcal A, C, W, Y (Adults)

A

Age 19 - >65: 1-2 doses depending on indication; for adults with additional risk factors or other indications

Consider:
- Asplenia/sickle cell, HIV+, immunocompromised: 2 dose series, at least 8 weeks apart and revaccinate Q5years if risk remains
- First-year college students who live in residential housing if not previously vaccinated at 16 years or older
- military recruits

1-2 doses depending on indication
- For pregnancy and immunocompromise if have additional risk factors or another indication; consider same for ESRD/on HD, heart/CV disease, chronic liver disease, diabetes, health care personnel, gay men

  • Recommended if lack of vaccine or lack of past infection: HIV+, asplenia/complement deficiencies
48
Q

Meningococcal B

A

19-23:

19 - >65 years: 2-3 doses depending on vaccine and indication

Consider:
- Asplenia/sickle cell, HIV+, immunocompromised: 2 dose series, at least 8 weeks apart and revaccinate Q5years if risk remains
- First-year college students who live in residential housing if not previously vaccinated at 16 years or older
- military recruits

  • Precaution in pregnancy; give if benefit outweighs risk
    2-3 doses depending on vaccine and indication
  • For immunocompromise if have additional risk factors or another indication; consider same for HIV+, ESRD/on HD, heart/CV disease, chronic liver disease, diabetes, health care personnel, gay men
  • Recommended if lack of vaccine or lack of past infection: asplenia/complement deficiencies
49
Q

Haemophilus influenzae type b (Hib) (Adults)

A

19 - >65: 1-3 doses depending on indication; recommended for adults with additional risk factors or other indications (i.e., anatomical or functional asplenia/sickle cell disease, stem cell transplant)

  • N/A in pregnancy

1 dose
- For immunocompromise if have additional risk factors or another indication; consider same for HIV+, ESRD/on HD, heart/CV disease, chronic liver disease, diabetes, health care personnel, gay men

  • Recommended if lack of vaccine or lack of past infection: immunocompromise, asplenia/complement deficiencies
  • Stem cell patients: 3 doses d/t immunocompromise
50
Q

Test Succes Tip:
1. Regarding secondary prevention, what is one of the most important primary care activities?

  1. Regarding the well-recognized guidelines with minor differences in screening recommendations, what should you focus on?
A
  1. Counseling about and providing opportunities for secondary prevention is one of the most important primary care activities
  2. Well-recognized guidelines often have minor differences in screening recommendations. When guidelines differ in recommendations, FOCUS YOUR STUDY ON THE OVERLAP, NOT ON THE DIFFERENCES!

Example: All sources recommend routine mammography for women at age 50 years.

51
Q

Formula for calculating Pack-Year History to Quantify Tobacco Use

A

of packs/day (PPD) x the # of years smoked

Ex: 2 PPD x 30 years = 60 pk/y history
0.5 PPD X 10 years = 5 pk/y history

52
Q

Suicide: True or false?

  1. Males represent nearly 80% of all completed suicides
  2. When compared with male suicide attempts, female attempts at suicide are approximately 2-3x more common
  3. The highest rate of completed suicide is found in teenage males
  4. Inquiring about suicidal ideation could precipitate the act
  • What should you keep in mind about screening questions in all ethnicities?
  • Has suicide rates increased?
    *Which age group has the highest completed suicide? Why?
A
  1. True. Men are more likely to succeed (guns and hanging)
  2. True. Women attempt more
  3. False. 65 years old men; 25% seen in healthcare provider in 24 hours
  4. False. Always ask about it!
  • In screening questions, take out ethnicity, the answer should not change!
  • Suicide rates have increased to 35%, will continue to increase due to the pandemic
  • 65+, highest completed (6x more success) due to widowed recently, sick spouse

Keep in mind, rate increases in every age group

53
Q

Is elder abuse reportable?

A

Yes.

54
Q

Stages of Change Theory

A

Prochaska and DiClemente: Stages of change

A transtheoretical model assesses an individual’s readiness to act on a new healthier behavior, and provides strategies, or processes of change, to guide the individual through the stages of change to action and maintenance.

Five stages of preparation and maintenance for change.
1. Precontemplation
2. Contemplation
3. Preparation
4. Action
5. Maintenance/relapse

55
Q

Precontemplation
1. Definition
2. Provider’s Action

A
  1. The patient is not interested in change and might not be aware that the problem exists or minimizes the problem’s impact
  2. Help patient to move toward thinking about changing the unhealthy behavior
56
Q

Contemplation
1. Definition
2. Provider’s action

A
  1. The patient is considering change and look at its positive and negative aspects. At the same time, the person often reports feeling “stuck” with the problem
  2. Help the patient to examine benefits and barriers to change
57
Q

Preparation
1. Definition
2. Provider’s action

A
  1. The patient exhibits some change baviors or thoughts and often reports feeling that he or she does not have the tools to proceed
  2. Assist patient in finding and using tools to help with change, continuing to work to lower barriers to change
58
Q

Preparation
1. Definition
2. Provider’s action

A
  1. The patient exhibits some change baviors or thoughts and often reports feeling that he or she does not have the tools to proceed
  2. Assist patient in finding and using tools to help with change, continuing to work to lower barriers to change
59
Q

Action
1. Definition
2. Provider’s action

A
  1. The patient is ready to go forth with change, often takes concrete steps to change but is inconsistent with carrying through
  2. Work with the patient on use of tools, encouraging the healthy behavior change, praising the positive, acknowledging reverting back to former behavior as a common but not insurmountable problem
60
Q

Maintenance/relapse
1. Definition
2. Provider’s action

A
  1. The patient learns to continue the change and has adopted and embraced the healthy habit. At the same time, relapse can occur, and the person learns to deal with backsliding
  2. continued positive reinforcement for the behavior change, put backsliding into perspective of a common but not insurmountable problem
61
Q

The “5 As”

  • When should you start asking about smoking?
  • On average, how many times does it take for a smoker to quit?
A

Successful intervention begins with identifying tobacco users and appropriate interventions based upon the patient’s willingness to quit

Ask - Identify and document tobacco use status for every patient at every visit

Advise - In a clear, strong, and personalized manner, urge every tobacco user to quit

Assess - Is the tobacco user willing to make a quit attempt at this time?

Assist - For the patient willing to make a quit attempt, use counseling and pharmacotherapy to help him or her quit

Arrange - Schedule follow-up contact, in person or by telephone, preferably within the first week after the quit date

  • > 12 years, ask about smoking at every single encounter
  • 10-11 tries to quit smoking for average smoker
62
Q

Leading causes of Death in the US in Age groups:

  1. Adolescents (10-34)
  2. Young adults (35-44)
  3. Older adults (45-64)
  4. All ages
A
  1. Unintentional injury (MVA, drowning)
    Suicide
    Malignancy/Homicide (15-34)
    Congenital abnormalities
    Homicide
  2. Unintentional injury
    Malignancy
    Heart disease
    Suicide
    Homicide
  3. Malignancy
    Heart disease
    Unintentional injury
    Suicide
    Liver disease
  4. Heart disease
    Malignancy
    Unintentional injury
    CLRD (chronic lower respiratory disease)
    Cerebrovascular
63
Q

Most common cancers:
- Males
- Females
- Highest mortality
- Most common

A
  • Prostate
  • Breast
  • Lung cancer –> screening, low dose CT
  • Skin cancer (melanoma)
64
Q

According to current nationally-recognized recommendations, when are the following cancer screenings are indicated?
1. Digital rectal exam
2. PAP test with HPV cotesting
3. Ovarian/endometrial biopsy
4. Annual PSA
5. Lung cancer
6. BRCA/breast cancer

A
  1. Never a screening. 3 stool samples at home; if abnormal –> colonoscopy
  2. Start PAP at 21 years; start HPV
  3. Only done in menopausal bleeding to assess endometrial cancer
  4. 55-69 years done annually; no benefit >69 years (none at 70)
  5. No indication for assessment if not associated with BA CA or gene mutation. *Give screening questionnaire (FHS-7), then refer to specialist; recommend assessment for women with a personal or family history of breast, ovarian, tubal, or peritoneal CA or those who have ancestry associated with BA CA susceptibility 1 and 2 (BRCA 1/2); if positive on risk assessment tool –> genetic counseling/testing
65
Q

Colorectal cancer screening

A

American Cancer Society
Initially in men and women at 45 - 75 years
Ages 76-85 years, individualized screening
>85 years, stop screening

Tests can include:
- Guaiac-based fecal occult blood test (gFOBT) or fecal immunochemical test (FIT) annually
- Stool DNA test (every 3 years)
- Colonoscopy (every 10 years)
- Flexible sigmoidoscopy (every 5 years)
- CT colonography (every 5 years)
- Double-contrast barium enema (DCBE) (every 5 years)

USPSTF
Screening starts at 50 years
Ages 76-85 years, individualized screening
>85 years, stop screening
- gFOBT or FIT annually
- FIT-DNA (every 1 to 3 years)
- Colonoscopy (every 10 years)
- Flexible sigmoidoscopy (every 5 years)
- CT colonoscopy (every 5 years)
- Flexible sigmoidoscopy with FIT (flexible sigmoidoscopy every 10 years plus FIT annually)

66
Q

Endometrial CA screening

A

American Cancer Society

All menopause women should be informed about risks and symptoms of endometrial cancer and encouraged to report unexpected
- vaginal bleeding
- vaginal discharge
- vaginal spotting
Screening tool: endometrial biopsy

If women have hereditary non-polyposis colon cancer (HNPCC), annual screening should be offered for endometrial CA with biopsy starting at 35 years

67
Q

Lung CA screening

A

American Cancer Society

Annual screening with low-dose CT is recommended for individuals 55-74 years who have a >/= 30 pack/year smoking history and who currently smoke
OR
It has been </= 15 years since quitting

Continue screening until 74 as long as patient is in good health

USPSTF
Annual screening with LDCT in ages 55-80 who has a 30 p/year smoking hx and currently smoke or who have quit within the last 15 years

Discontinue screening if >15 years since quit and/or develops a health problem that substantially limits life expectancy or the ability/willingness to have curative lung surgery

68
Q

Breast Cancer Screening Guidelines
American Cancer Society

A

Begin annually at 45 years (can start annually at 40) until 54 years, then biennially for as long as woman is in good health and have a life expectancy of at least 10 years

40-44 years: can start screening/annual mammography if they wish to

69
Q

Breast Cancer Screening Guidelines
USPSTF

A

Age 50-74 years: biennial screening

Unable to assess additional benefits and harms in women >/= 75 years

70
Q

Breast Cancer Screening Guidelines
American Geriatrics Society

A

For women in average-better health with an estimated life expectancy of 5+ years –> offer mammography every 1-2 years up to age 85 years.

> /=85: reserve screening for women who most likely to benefit by virtue of excellent health and functional status and for those who feel strongly that they will benefit from screening

71
Q

Cervical Cancer Screening
1. Why should screening before age 21 be avoided?

Guidelines per ASCCP, ACOG, ACS, USPSTF

A
  1. Women <21 years are at very low risk for cancer. Screening may lead to unnecessary and harmful evaluation and treatment. Although HPV infection is high among sexually active adolescents, the immune system clears HPV within 1-2 years. Due to immature cervix, higher incidence of HPV-related precancerous lesions (dysplasia), but these usually resolve on their own.
  • Start screening at age 21; avoid in <21 years.
  • PAP should be done every 3 years (standard or with liquid-based cytology)
  • Women with certain risk factors may need earlier and more frequent screening including those HIV+, immunocompromised, exposed to DES in utero, including those treated for cervical intraepithelial neoplasia (CIN) 2 & 3, or cervical cancer –> Not recommended (NR) by USPSTF but ok by everyone else
  • Stop screening at >/=65 years who have had adequate negative cytology results and not otherwise at high risk for cervical cancer
  • If hx of CIN 2 or CIN 3, continue to test at least 20 years after abnormality was found (ACS stats stop >/= 65 years who have had regular screening in past 10 years with no serious pre-cancers like CIN 2/3 found in the past 20 years)
  • Women who have had a total hysterectomy (including cervix removal) should stop screening as long as not for cancer
  • Women with hysterectomy without cervix removal should continue to follow standard guidelines (yes by ACS; NR by ASCCP, ACOG, or USPSTF)
  • Women who have been vaccinated against HP should follow same screening guidelines (NR by USPSTF but everyone else okay)